Asston Pharmaceuticals intimates BSE of board meeting on May 29, 2026, to approve FY26 and Q4 results.
Agenda includes approval of audited financial statements for year and quarter ended March 31, 2026.
Board will also consider statement of funds deviation per SEBI LODR Regulation 32.